Al­ny­lam sues Mod­er­na and Pfiz­er again over Covid-19 vac­cine patent in­fringe­ment

The patent bat­tle over Covid-19 vac­cine de­liv­ery tech­nol­o­gy in­ten­si­fied yes­ter­day af­ter Al­ny­lam Phar­ma­ceu­ti­cals yet again ac­cused Mod­er­na and Pfiz­er of vi­o­lat­ing patents.

In two sep­a­rate law­suits filed Tues­day, Al­ny­lam said that the vac­cine mak­ers in­fringed on its patent re­lat­ing to lipid nanopar­ti­cle tech­nol­o­gy that has been cen­tral to de­liv­er­ing mR­NA in­to hu­man cells.

“The Al­ny­lam LNP Tech­nol­o­gy is foun­da­tion­al to the suc­cess of the re­cent­ly de­vel­oped mes­sen­ger RNA (‘mR­NA’) based COVID vac­cines,” ac­cord­ing to the law­suits filed in Delaware fed­er­al court.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.